论文部分内容阅读
目的:应用乳腺癌组织特异性标志物细胞角蛋白(Cytokeratin,CK19)检测腋淋巴结阴性乳腺癌(Axillarylymph nodes negative breast cancer,ALNNBC)骨髓中的微转移癌,并探讨其与临床病理因素之间的关系。方法:采用RT-PCR方法检测86例ALNNBC骨髓中CK19mRNA的表达,并以MCF-7乳腺癌细胞为阳性参考检测该方法的灵敏度。结果:ALNNBC骨髓中CK19mRNA的阳性表达率为30.23%(26/86),该方法检测骨髓微转移的灵敏度可达1/107,肿瘤大小与微转移发生率正相关(P<0.05),年龄、病理类型、Her-2表达、ER/PR状态及p53表达等与微转移无关。结论:CK19可作为乳腺癌骨髓微小转移检测的标志物;ALNNBC微转移与肿瘤大小密切相关。
OBJECTIVE: To detect the micrometastasis in the bone marrow of axillary lymph nodes negative breast cancer (ALNNBC) by using cytokeratin (CK19), a specific marker of breast cancer tissue, and to explore its relationship with clinicopathological factors relationship. Methods: The expression of CK19 mRNA in bone marrow of 86 patients with ALNNBC was detected by RT-PCR. The sensitivity of the method was tested by MCF-7 breast cancer cells as a positive reference. Results: The positive rate of CK19 mRNA in bone marrow of ALNNBC was 30.23% (26/86). The detection sensitivity of bone marrow micrometastasis was 1/107. The size of tumor was positively correlated with the incidence of micrometastasis (P <0.05) The pathological types, Her-2 expression, ER / PR status and p53 expression have nothing to do with micrometastasis. Conclusion: CK19 can be used as a marker of micrometastasis in bone marrow of breast cancer. Micrometastasis of ALNNBC is closely related to tumor size.